Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Recombinant CCL2 as a novel treatment strategy for bladder cancer

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Recent approval of immunotherapies has revolutionized the approach to managing bladder cancer (BC). Nevertheless, complete response is observed in only a minority of patients and there are no unambiguous biomarkers to guide treatment selection. Currently, a major obstacle in the field is limited knowledge of signals that regulate immune pathways during BC development and growth. The chemokine CCL2 (C-C motif ligand 2) is best known for its ability to induce trafficking of immune cells by binding its primary receptor, CCR2. The recruitment of immunosuppressive cells by CCL2 signaling, promotes cancer in several tumor types. In bladder, however, we show an unexpected finding that CCL2 is protective against BC development and growth. Further, we show that CCL2’s primary receptor, CCR2, is also implicated in bladder cancer defense. We hypothesize that CCL2 mediates protection against bladder tumor growth by recruiting CCR2+ T cells to the bladder environment. To address this hypothesis two specific aims are proposed. In Aim 1, we define mechanisms underlying BC protection by CCR2+ T cells. We utilize the MB49 orthotopic mouse bladder tumor model and antibody depletion studies of T cell subsets and adoptive T cell transfers to define the tumor protective roles of these CCR2+ T cells subsets. Aim 2 investigates contribution of CCL2 towards CCR2-mediated BC protection using antibody depletion of CCL2 (?CCL2) and recombinant CCL2 (rCCL2) in wildtype (WT) versus CCR2KO mice. It also tests a novel nanoparticle formulation of recombinant CCL2 to treat BC. Successful completion of this proposal will elucidate mechanisms underlying CCL2’s protection from BC growth. Data accrued from this proposal are rapidly translatable and could lead to a novel treatment strategies and/or more effective use of existing therapies for patients with BC.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer


USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
[The association between SORL1 and advanced bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to Takanobu UTSUMI

USD 26,335
2019 - 2021



    1107 Immunology


    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC

    Urologic Diseases




    2.1 Biological and endogenous factors

  • Health Research Areas


  • Broad Research Areas

    Basic Science